MedStar Authors catalog › Details for: Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. [Review]
Normal view MARC view ISBD view

Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. [Review]

by Pasieka, Helena B.
Citation: ; Journal of the American Academy of Dermatology. 83(4):1150-1159, 2020 Oct..Journal: Journal of the American Academy of Dermatology.Published: ; 2020; ; ISSN: 0190-9622.Full author list: Anadkat MJ; Chen ST; Fox LP; Harp J; Merola JF; Micheletti RG; Nambudiri VE; Niaki OZ; Pasieka HB; Rosenbach M; Shinohara MM.UI/PMID: 32569797.Subject(s): Advisory Committees/st [Standards] | Symptom Flare Up | Societies, Medical/st [Standards] | *Skin Diseases/th [Therapy] | Skin Diseases/im [Immunology] | *Practice Guidelines as Topic | Pneumonia, Viral/vi [Virology] | *Pneumonia, Viral/pc [Prevention & Control] | Pneumonia, Viral/im [Immunology] | Pneumonia, Viral/ep [Epidemiology] | *Pandemics/pc [Prevention & Control] | Interdisciplinary Communication | *Immunosuppression/st [Standards] | Immunosuppression/mt [Methods] | Immunosuppression/ae [Adverse Effects] | Humans | Hospitalists/st [Standards] | Disease Susceptibility/im [Immunology] | *Dermatology/st [Standards] | Dermatology/mt [Methods] | Dermatologists/st [Standards] | Decision Making, Shared | Coronavirus Infections/vi [Virology] | *Coronavirus Infections/pc [Prevention & Control] | Coronavirus Infections/im [Immunology] | Coronavirus Infections/ep [Epidemiology] | Clinical Decision-Making | Betacoronavirus/py [Pathogenicity] | Betacoronavirus/im [Immunology]Institution(s): MedStar Washington Hospital CenterDepartment(s): DermatologyActivity type: Journal Article.Medline article type(s): Journal Article | ReviewOnline resources: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/j.jaad.2020.06.051 (Click here) Abbreviated citation: ; J Am Acad Dermatol. 83(4):1150-1159, 2020 Oct.Abstract: Dermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of the SARS-CoV-2 pandemic. Though the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of such agents in COVID-19 are scarce. This article reviews and offers guidance based upon currently available safety data, and the most recent COVID-19 outcome data, in patients with immune-mediated dermatologic disease. The interdisciplinary panel of experts emphasize a stepwise, shared decision-making approach in the management of immunosuppressive therapy. The goal of this article is to help providers minimize the risk of disease flares while simultaneously minimizing the risk of iatrogenic harm during an evolving pandemic. Copyright (c) 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Powered by Koha